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Nitric oxide (NO) is synthesized from L-arginine and molecular oxygen by a fam-ily of three enzymes: NOS1, NOS2, and 
NOS3.1,2 NO is the most powerful endogenous va-
sodilator known. It can also inhibit the adhesion, ag-
gregation, and recruitment of platelets; inhibit vascular 
smooth muscle cell migration and growth; regulate 
some vessel–platelet interactions; and limit the oxida-
tion of atherogenic low-density lipoproteins.1 These 
actions are all mediated by the activation of soluble gua-
nylate cyclase and the consequent increase in the con-
centration of cyclic GMP in target cells.3 
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BACKGROUND AND OBJECTIVES: Endo-derived nitric oxide (NO) is synthesized from L-arginine by endothe-
lial nitric oxide synthase (NOS3). Since reduced NO synthesis in endothelial cells has been implicated in the 
development of coronary atherosclerosis, we investigated the association of NOS3 gene polymorphisms and 
coronary artery disease (CAD) in an Iranian population.
SUBJECTS AND METHODS: We studied the NOS3 gene Glu298Asp polymorphism in 241 CAD patients with 
positive coronary angiograms (i.e., >50% stenosis affecting at least one coronary vessel) in Shahid Rajaee Heart 
Hospital and 261 control subjects without a history of symptomatic CAD. The NOS3 gene polymorphism was 
analyzed by polymerase chain reaction and restriction fragment length polymorphism. Lipid profile and other 
risk factors were also determined.
RESULTS: The genotype frequencies of Glu298Asp polymorphism for Glu/Glu, Glu/Asp, and Asp/Asp were 
61.3%, 32.2%, and 6.5%, respectively, in control subjects, and 46.5%, 42.7%, and 10.8% in CAD patients, 
respectively. The genotype frequencies differed significantly between the two groups (P=.003). The frequencies 
of the Asp alleles were 32.2% and 22.6% for CAD patients and control subjects, respectively; the difference 
between the two groups was statistically significant (P=.001; odds ratio=1.6). Plasma lipids, except HDL-C, were 
also significantly increased in the CAD groups.
CONCLUSION: These results suggest that CAD is associated with Glu298Asp polymorphism of the NOS3 gene 
in our population and that this polymorphism is an independent risk factor for CAD.
The constitutive endothelial nitric oxide synthase 
(NOS3) is expressed in the endothelium and is en-
coded by a 26-exon gene located on chromosome 7q35 
to 36; the gene, with a total size of 21 kb, encodes an 
mRNA of 4052 nucleotides.4,5 The NOS3 gene is ex-
pressionally and functionally regulated through multi-
ple regulatory steps and entails several polymorphisms, 
some of which bear functional consequences.4 
Reduction in basal NO release is known to predis-
pose humans to atherosclerosis, hypertension, throm-
bosis, and vasospasm. On the other hand, high circulat-
ing NO concentrations, which occur with excessive in-
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ducible NOS expression under pathological conditions, 
are generally toxic.6 Emerging evidence suggests that 
coronary artery disease (CAD) is related to defects in 
the generation or function of NO. Markedly increased 
NO concentrations are reported to be associated with 
endotoxic shock and exaggerated inflammatory reac-
tions, which may lead to acute hepatic dysfunction and 
predispose humans to asthma and cardiomyopathy.6,7 
In general, NOS3 gene polymorphisms have been 
reported to act as ‘susceptibility genes’ in various car-
diovascular and pulmonary diseases.7 GT substitution 
in exon 7 of codon 298,8 4a/b polymorphism in intron 
4,9,10 T-786C mutation in the 5´-flanking region,11,12 
and high numbers of CA repeat in intron 13 of the 
NOS3 gene are also associated with an excess risk for 
CAD.13 Among them, a common variant located in 
exon 7 (G984T) of the NOS3 gene that modifies its 
coding sequence (Glu298Asp) has been linked by sev-
eral groups to the risk for CAD and acute myocardial 
infarction (MI). On the other hand, other studies failed 
to show any relationship between the Asp variant and 
the risk for atherosclerosis.14  In the present study, we 
investigated the associations between the occurrence 
and severity of angiographically defined CAD and the 
Glu298Asp polymorphism. 
SUBJECTS AND METHODS
Patients recruited in this study (n=241; 174 males and 
67 females) were those who had undergone coronary an-
giography because of recent MI or angina. They were se-
lected at Tehran Shahid Rajaee Heart Hospital after be-
ing angiographically identified (>50% stenosis affecting 
at least one coronary vessel) as having CAD. The con-
trol group consisted of 261 individuals (187 males and 
74 females) within the same age range as the patients; 
they were selected at the same hospital after screening 
to eliminate individuals with a history of chest pain, dia-
betes, hypertension, or any other specific illness. Clinical 
details of these groups are shown in Table 1. All par-
ticipants were interviewed and data on smoking habits, 
blood pressure, lipid profile, and any family history of 
CAD were recorded. The study protocol was approved 
by the Ethics Committee of Iran University of Medical 
Sciences and written informed consent was taken from 
all patients and healthy individuals.
Blood samples were obtained from all subjects af-
ter 12 hours of fasting and placed in EDTA tubes 
and stored at −70°C until the time of assay. Serum 
concentrations of triglyceride (TG), total cholesterol, 
low-density lipoprotein (LDL-C), and high-density 
lipoprotein (HDL-C) were measured by standard 
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methods (ZiestChem Diagnostics, Iran) in the clini-
cal laboratory of the hospital. Genomic DNA was 
tracted from peripheral blood leukocytes by a standard 
method (Roche Blood Kit, Germany). Two oligonucle-
otide primers (sense) 5´-GAC CCT GGA GAT GAA 
GGC AGG AGA-3´and (antisense) 5´-ACC TCC 
AGG ATG TTG TAG CGG TGA-3´ based on the 
flanking sequences of the exon 7 in the NOS3 gene 
were used to amplify the corresponding DNA fragment 
by the polymerase chain reaction (PCR).15 The reaction 
was performed in a 25-µl final volume and contained 
25 pmol of each primer, 0.2 mmol of each deoxynucleo-
side triphosphate (Roche, Germany),1.5 U Taq DNA 
polymerase (Fermentas, Lithuania), 50 mmol/l KCL, 
2.5 mmol/l MgCl2, 10 mmol/l Tris-Hcl (pH=8.3), and 
400 ng of genomic DNA. The reaction was done ac-
cording to the following protocol: initial denaturation 
at 94°C for 5 min, 30 cycles of denaturation at 94°C for 
30 s, annealing at 61°C for 30 s, extension at 72°C for 
30 s, and final extension at 72°C for 6 min. The 517-
bp PCR fragments were digested with BanII restriction 
enzyme for 16 hours at 37°C. The wild-type allele (G) 
has no BanII cleavage site, whereas the PCR product 
was cleaved into two fragments of 346 and 171 bp in 
the presence of the T984.
All statistical analysis was performed with SPSS v. 
11.5. Numeric data are presented as mean (standard 
Table 1. Clinical characteristics of the studied population. 
CAD patients Controls P value 
No. of subjects 241 261   
Age (years) 53.32 (9.4) 51.8 (8.9) NS 
BMI (kg/m2) 27.1 (6.1) 27.5 (19.9) NS 
Smoking n (%) 88 (36.5) 66 (25.3) .004 
Family history n (%) 92 (38) 68 (26)  .002 
DBP (mm Hg) 85.4 (13.6) 76 (6.7) .001 
SBP (mm Hg) 129.9 (24.3) 117.5 (139) .001 
Cholesterol (mg/dl) 203.8 (45.6) 188.1 (32.3) .001 
TG (mg/dl) 204 (110.5) 169.5 (87.7) .001 
LDL-C (mg/dl) 116.9 (37.2) 105.6 (33.7) .001 
HDL-C (mg/dl) 46.9 (10.4) 48.3 (10.8) NS 
LDL-C/HDL-C 2.63 (0.93) 2.34 (0.88) .006 
Values are mean (SD); BMI=body mass index; SBP=systolic blood pressure; 
DBP=diastolic blood pressure; TG=triglyceride; LDL-C=LDL cholesterol; HDL-C=HDL 
cholesterol; NS=non-significant.
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deviation). The differences between groups were ex-
amined by the chi-square test or an independent t test 
as appropriate. ANOVA was used for comparisons 
among the three groups. Allele frequencies were esti-
mated by the gene-counting method. The frequencies 
of the alleles and genotypes were compared between 
patient and control groups by the chi-square test when 
appropriate. The odds ratio (OR) and 95% confidence 
intervals (CI) were also estimated. The chi-square test 
was used to examine the deviation of genotype distri-
bution from the Hardy-Weinberg equilibrium. Logistic 
regression analysis was used to assess the independent 
effect of each risk factor in CAD. 
RESULTS
The clinical characteristics of the population are shown 
in Table 1. Control subjects were matched to the case 
patients by gender and age. Although BMI and HDL-C 
showed no significant differences between the patients 
and the control subjects, systolic blood pressure (SBP) 
and diastolic blood pressure (DBP), triglyceride, total 
cholesterol, LDL-C, and LDL-C/HDL-C in patients 
were significantly higher. The frequency of cigarette 
smoking and family history of CAD in patients were 
higher than in controls.
The genotype frequencies of Glu298Asp polymor-
phism in control subjects were 61.3% for Glu/Glu, 
32.2% for Glu/Asp, and 6.5% for Asp/Asp. On the 
other hand, in CAD patients, the genotype frequen-
cies were 46.5% for Glu/Glu, 42.7% for Glu/Asp, and 
10.8% for Asp/Asp (Table 2). Although the distribu-
tion of genotypes in both the CAD and the control 
groups satisfied the Hardy-Weinberg equilibrium, the 
G894T polymorphism of the NOS3 gene was signifi-
cantly associated with the presence of CAD in our pa-
tients (χ²=11.5, P=.003). 
The frequencies of the Glu and Asp alleles were 32.2% 
and 67.8% for CAD patients and 22.6% and 77.4% for 
the control subjects, respectively; the differences be-
tween the groups were statistically significant (χ²=11.6, 
P=.001, odds ratio=1.6). We analyzed the frequencies 
of Glu/Asp and Asp/Asp genotypes in CAD patients 
and control subjects according to age (age≤55 years and 
age >55 years) and found that the frequencies of Glu/
Asp and Asp/Asp genotypes were significantly higher 
in patients of age≤55 years(χ²=30.3, P=.000, odds 
ratio=3.84) (Table 3). The logistic regression analysis 
revealed that the NOS3 mutant allele, smoking, fam-
ily history, DBP, and LDL-C were independent risk 
factors for CAD (P=.004, P=.001, P=.006, P=.001, 
and P=.001, respectively), whereas DBP, cholesterol, 
HDL-C, and TG were not independent risk factors for 
CAD (Table 4). 
DISCUSSION
In addition to established risk factors, genetic risk 
factors may have important roles in the pathogenesis 
of coronary atherosclerosis and acute MI. Using the 
Table 2. Genotype and allele frequencies of Glu298Asp polymorphism of the eNOS gene 
in CAD patients and controls.
CAD patients Controls  Odds ratio  (95% CI) P value χ
2 
Glu298 Asp  
polymorphism       .003 11.5 
Glu/Glu, n (%) 112 (46.5) 160 (61.3)       
Glu/Asp, n (%) 103 (42.7) 84 (32.2)       
Asp/Asp, n (%) 26 (10.8) 17 (6.5)       
Total 241 261 1.83 (1.28-2.6) .001 111.1 
Glu/Glu, n (%) 112 (46.5) 160 (61.3)       
Glu/Asp+Asp/Asp, n (%) 129 (53.5) 101 (38.7)       
Total 241 261 1.6 (1.23-2.2) .0001 11.6 
allele         
Glu (%) 67.8 77.4
Asp(%) 32.2 22.6       
Total 100 100       
Table 3. Genotype frequencies of Glu298Asp polymorphism of the eNOA gene in CAD 
patients and controls in different ages. 
  CAD patients Controls Odds ratio  (95% CI) P value χ
2 
Glu298Asp  
polymorphism           
Age≤55 years     3.84 (2.4-6.3) .001 30.3 
Glu/Glu, n (%) 36 (28) 104 (60)       
Glu/Asp+Asp/Asp, n (%) 93 (72) 70 (40)       
Total 129 174       
Age>55 years     0.86 (0.47-1.56) .6 0.27 
Glu/Glu, n (%) 76 (68) 56 (64)       
Glu/Asp+Asp/Asp, n (%) 36 (32) 31 (36)       
Total 112 87       
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approach of epidemiological studies, it is possible to 
identify weak susceptible genes in polygenic diseases 
like coronary heart disease.16 In the last decade, the 
potential link between an increasing number of gene 
variants and coronary heart disease has been analyzed 
by several investigators. Due to the protective roles of 
NO against important events during atherogenesis, 
the NOS3 gene has been identified as  also having 
other roles in deciding susceptibility to coronary heart 
disease.17,18
There are many polymorphisms of the NOS3 
gene that have been investigated in relation to CAD. 
Yashimura et al described a point mutation of guanine 
to thymine at nucleotide 1998 in exon 7 of the NOS3 
gene that resulted in replacement of glutamic acid by 
aspartic acid at codon 298.8 Later investigations also 
described other polymorphisms in the 5’ flanking and 
some introns of the NOS3 gene. Other studies ana-
lyzed the relation of the NOS3 gene variation with the 
risk of CAD. In an Australian population, Cai et al did 
not detect any association between NOS3 gene poly-
morphism and the risk of CAD.19 Hibi et al showed 
that patients who are homozygous for the Glu298Asp 
polymorphism might be genetically predisposed to 
acute MI; however, this mutation apparently is not 
related to the severity of coronary atherosclerosis.15 In 
contrast, Hingorani et al observed an excess of homo-
zygotes for Asp298 variant among patients with CAD. 
In comparison to Glu298 homozygotes, homozygosity 
Table 4. Multiple logistic regression analysis with forward stepwise selection (Wald). 
Variable B SE Wald df Significance Exp (B) 
eNOS mutant allele 0.61 0.21 8.3 1 .004 1.84 
Cigarrette smoking 0.85 0.23 13.4 1 .001 2.34 
Family history 0.64 0.23 7.5 1 .006 1.9 
Diastolic blood 
pressure 0.1 0.012 69.2 1 .001 1.1 
LDL-C 0.12 0.003 15.9 1 .001 1.01 
Constant 9.7 1.05 84.3 1 .001 0.000 
for Asp298 was associated with an odds ratio of 4.2 
(95% CI: 2.3 to 7.9).10 Lembo et al also detected the 
association of Glu298Asp polymorphism with the risk 
of CAD in Italy.20 Gardemann showed that younger 
T allele carriers of the NOS3 Glu298Asp gene poly-
morphism with various coronary high-risk profiles had 
an increased risk of CAD and/or MI.21 In some of the 
other studies, such as that by Nassar et al in Canada,22 
Schomoelzer et al in Australia,23 and Jaramillo 
et al in Chile,24 no associations were found between 
Glu298Asp polymorphism and the risk of CAD. In 
contrast, Colombo et al,14 Kerkeni et al,25 Cam et al,26 
and Berdeli et al27 detected a link between this poly-
morphism and CAD in Italian, Tunisian, and Turkish 
populations. In our previous study, we found that 4a/b 
polymorphism was not an independent risk factor for 
CAD in our population.28 In the present study, we have 
shown that Glu298Asp polymorphism is an indepen-
dent risk factor for CAD in this Iranian population, 
especially in younger patients (age≤55 years).
The frequency of the Asp allele was approximately 
0.23 in our population, which is very similar to that pre-
viously reported in a Tunisian population (0.22);25 and 
slightly higher than that observed in Turkish (0.17)27 
and Indian (0.15)29 populations and lower than that 
in the British (0.31),10 Italian (0.30),14 and Canadian 
populations (0.43).22 
In conclusion, our results show that genotype fre-
quencies for Glu/Glu, Asp/Glu, and Asp/Asp, and 
also Asp allele frequency, are significantly different 
between individuals with and without CAD. We have 
also shown that the Asp allele of NOS3 Glu298Asp 
polymorphism and DBP are independent risk fac-
tors for CAD. In our study, the sample size was small 
thus; a larger number of patients and controls needs to 
be examined to confirm the association between this 
polymorphism and CAD. 
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